Blog
RSS FeedPosted by Michael Wonder on 15 Oct 2019
Accounting for hope: using ‘mean survival gain’ to price new cancer drugs
14 October 2019 - Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But ...
Posted by Michael Wonder on 11 Oct 2019
ICER releases updated draft evidence report on rheumatoid arthritis therapies
11 October 2019 - Public comment period extended through 8 November 2019; public meeting now to take place on 9 December ...
Posted by Michael Wonder on 08 Oct 2019
Humira, Rituxan top list of U.S. costliest drug price increases
8 October 2019 - AbbVie Inc’s arthritis drug Humira and Roche's cancer drug Rituxan top the list of seven treatments ...
Posted by Michael Wonder on 08 Oct 2019
ICER identifies costliest US drug-price hikes that are not supported by new clinical evidence
8 October 2019 - In 2017 and 2018, out of nine identified drugs that had substantial price increases on top of ...
Posted by Michael Wonder on 01 Oct 2019
ICER posts draft scoping document for the assessment of treatments for cystic fibrosis
30 September 2019 - Document open to public comment until 21 October 2019. ...
Posted by Michael Wonder on 29 Sep 2019
ICER posts draft scoping document for the assessment of treatments for ulcerative colitis
27 September 2019 - Document open to public comment until 18 October 2019. ...
Posted by Michael Wonder on 26 Sep 2019
ICER releases draft evidence report on rheumatoid arthritis therapies
26 September 2019 - Public comment period now open until 24 October 2019; requests to make oral comment during public ...
Posted by Michael Wonder on 12 Sep 2019
ICER publishes evidence report on additive cardiovascular disease therapies
12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...
Posted by Michael Wonder on 11 Sep 2019
ICER releases draft evidence report on diabetes therapies
11 September 2019 - Public comment period now open until 8 October 2019; Requests to make oral comment during public meeting ...
Posted by Michael Wonder on 10 Sep 2019
ICER's blasted pharma pricing for years, but now drug makers are 'rolling up their sleeves' to cooperate
10 September 2019 - Sanofi and Regeneron's next-gen cholesterol drug Praluent never lived up to early expectations, and its price ...
Posted by Michael Wonder on 09 Sep 2019
As value assessment frameworks evolve, are they finally ready for prime time?
9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...
Posted by Michael Wonder on 09 Sep 2019
Achieving appropriate model transparency: challenges and potential solutions for making value‑based decisions in the United States
5 September 2019 - Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the ...
Posted by Michael Wonder on 08 Sep 2019
ICER to assess treatments for cystic fibrosis
6 September 2019 - Report will be subject of California Technology Assessment Forum meeting in April 2020; open Input now being ...
Posted by Michael Wonder on 08 Sep 2019
ICER to assess treatments for ulcerative colitis
6 September 2019 - Report will be subject of CTAF meeting in June 2020; open Input now being accepted until 24 ...
Posted by Michael Wonder on 01 Sep 2019
ICER posts draft scoping document for the assessment of treatments for sickle cell disease
30 August 2019 - Document open to public comment until 20 September 2019. ...